re: sydney herald article Not sure if article has been posted...here it is
SciGen share price doubles
October 10, 2005 -
*
Shares in SciGen Ltd have more than doubled after the biopharmaceutical company announced a $US145 million ($A190.51 million)-plus distribution deal into China for its Hepatitis-B vaccine, its first foray into the country.
The Singapore-based company, which is listed on the Australian Stock Exchange (ASX), has signed a non-exclusive agreement with China-based Hefei Life Science Park Investment and Development Company (HID).
Under the commercialisation deal, HID has committed to order and pay for SciGen's Hepatitis-B vaccine - Sci-B-Vac - in either bulk antigen or dispensed dose form for the next seven years.
SciGen expects this to generate revenue of at least $US210 million ($A275.92 million) if the vaccine is distributed in dispensed doses over that period, or $US145 million ($A190.51 million), if in bulk antigen, essentially the raw material.
At 1249 AEST, shares in SciGen had gained 5.2 cents to 9.8 cents.
SciGen chief executive Saul Mashaal said the deal was significant for the company, which will still be able to sell the product through other distributors in China.
"The sales targets to which HID has agreed are substantive, yet the agreement allows SciGen considerable control over the future of Sci-B-Vac sales and marketing in China," Mr Mashaal said.
© 2005 AAP
- Forums
- ASX - By Stock
- SIE
- no approval yet in china ??
no approval yet in china ??, page-7
-
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
TG1
TechGen Metals kicks off airborne geophys survey at Sally Downs copper play – a first for the permit
AVH
Avita boosts skin restoration product portfolio with 'dermal matrix' – a kind of next-level gauze made of fake skin